European regulators have approved the use of epidermal (cefiderocol), an antibiotic developed for the treatment of complicated urinary tract infections in adult patients. The drug can be used in infections caused by gram-negative bacteria, therapeutic options which are limited, PharmaTimes writes.
This drug is already approved in the United States, and the results of clinical trials confirm its efficacy and favorable safety profile. According to the KEY held with the participation of 448 patients, the use of a new drug provided a recovery of 72.6% of patients 7 days after completion of treatment, whereas in the control group, the use of alternative antibiotics after a week of therapy recovered only 54,6% of patients. The most common adverse events of epidermal had diarrhea, constipation, nausea, vomiting, reactions at the injection site and some others.
Currently, a major concern of the medical community is causing the spread of drug resistance of bacteria, so to market a new antibiotic is a major event.